Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 22.0 kDa. The protein migrates as 35-45 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human OX40 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
The purity of Human OX40 Protein, His Tag (Cat. No. OX0-H5224) is more than 85% and the molecular weight of this protein is around 32-44 kDa verified by SEC-MALS.
Immobilized Human OX40 Protein, His Tag (Cat. No. OX0-H5224) at 2 μg/mL (100 μL/well) can bind Human OX40 Ligand, Fc Tag, premium grade (Cat. No. OXL-H5266) with a linear range of 0.1-2 ng/mL (QC tested).
Immobilized Human OX40 Protein, His Tag (Cat. No. OX0-H5224) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human OX40 Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (Routinely tested).
Immobilized Human OX40 Protein, His Tag (Cat. No. OX0-H5224) at 2 μg/mL, add increasing concentrations of CTLA-4 x OX40 bispecific antibody in 50% Human serum and then add Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 4 ng/mL (Intact assay, Routinely tested).
Loaded Human OX40 Ligand, His Tag (Cat. No. OXL-H52Q8) on AR2G Biosensor, can bind Human OX40 Protein, His Tag (Cat. No. OX0-H5224) with an affinity constant of 0.15 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Anti-OX40 MAb(Human IgG1) on AHC Biosensor, can bind Human OX40 Protein, His Tag (Cat. No. OX0-H5224) with an affinity constant of 6.03 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
SAR-442970 | SAR-442970 | Phase 1 Clinical | Sanofi | Inflammation | Details |
SHR-1806 | SHR-1806 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | Neoplasms | Details |
KN-052 | KN-052 | Phase 1 Clinical | Solid tumours | Details | |
Recombinant human anti-OX40 monoclonal antibody (Livzon Group) | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Neoplasms | Details | |
Tavolimab | MEDI-0562 | Phase 1 Clinical | Medimmune | Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Squamous Cell; Carcinoma, Squamous Cell; Melanoma | Details |
SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Takeda Pharmaceutical Co Ltd, Shattuck Labs Inc | Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma | Details |
Telazorlimab | GBR-830; ISB-830 | Phase 2 Clinical | Glenmark Pharmaceuticals Ltd | Dermatitis, Atopic | Details |
HFB-3010(HiFiBiO Therapeutics) | HFB-3010; HFB-301001 | Phase 1 Clinical | HiFiBiO Therapeutics | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Sarcoma; Uterine Neoplasms; Carcinoma, Hepatocellular | Details |
INBRX-106 | ES-102; ES102; INBRX-106 | Phase 1 Clinical | Inhibrx | Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
BAT-6026 | BAT-6026 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd, Bio-Thera Solutions Ltd | Solid tumours; Neoplasms | Details |
Revdofilimab | ABBV-368; PR-1628103 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
ATOR-1015 | ADC-1015; ATOR-1015 | Phase 1 Clinical | Alligator Bioscience Ab | Solid tumours; Neoplasms | Details |
Cudarolimab | IBI-101 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
FS-120 | FS-120 | Phase 1 Clinical | F-Star | Neoplasms; Neoplasm Metastasis | Details |
GSK3174998 | GSK3174998; GSK 3174998; GSK-3174998 | Phase 2 Clinical | Glaxosmithkline Plc | Neoplasms; Multiple Myeloma | Details |
EMB-09 | EMB-09 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Solid tumours | Details |
INCAGN-1949 | INCAGN-1949 | Phase 2 Clinical | Agenus Inc, Ludwig Institute For Cancer Research | Solid tumours; Pancreatic Neoplasms; Neoplasms; Neoplasm Metastasis | Details |
BMS-986178 | BMS-986178 | Phase 1 Clinical | Bristol-Myers Squibb Company | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Solid tumours; Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
IMG-007 | IMG-007 | Phase 1 Clinical | Hutchmed (China) Ltd | Dermatitis, Atopic | Details |
Ivuxolimab | PF-8600; PF-04518600 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Solid tumours; Ovarian Neoplasms; Carcinoma; Carcinoma, Renal Cell; Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Lymphoma, Follicular; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
MEDI-6469 | MEDI-6469; AGX-051 | Phase 1 Clinical | Providence Cancer Center, AgonOx Inc, Astrazeneca Plc, Providence Health & Services | Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Neoplasm Metastasis; Melanoma | Details |
Rocatinlimab | KHK-4083; AMG-451 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd, Amgen Inc | Abdominal Pain; Inflammatory Bowel Diseases; Gastrointestinal Diseases; Digestive System Diseases; Autoimmune Diseases; Colitis; Colonic Diseases; Colitis, Ulcerative; Dermatitis, Atopic; Intestinal Diseases | Details |
BGB-A445 | BGB-A445 | Phase 2 Clinical | Beigene Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
Recombinant human anti-OX40 monoclonal antibody (Eucure Biopharma) | YH-002 | Phase 1 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.